Erik C. Schimmel

1.9k total citations · 1 hit paper
18 papers, 1.3k citations indexed

About

Erik C. Schimmel is a scholar working on Pulmonary and Respiratory Medicine, General Health Professions and Radiation. According to data from OpenAlex, Erik C. Schimmel has authored 18 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Pulmonary and Respiratory Medicine, 5 papers in General Health Professions and 5 papers in Radiation. Recurrent topics in Erik C. Schimmel's work include Prostate Cancer Treatment and Research (10 papers), Prostate Cancer Diagnosis and Treatment (9 papers) and Advanced Radiotherapy Techniques (5 papers). Erik C. Schimmel is often cited by papers focused on Prostate Cancer Treatment and Research (10 papers), Prostate Cancer Diagnosis and Treatment (9 papers) and Advanced Radiotherapy Techniques (5 papers). Erik C. Schimmel collaborates with scholars based in Netherlands, United States and Italy. Erik C. Schimmel's co-authors include Floris J. Pos, Luca Incrocci, Shafak Aluwini, Wendimagegn Alemayehu, Ben Heijmen, Augustinus D. G. Krol, Wilma D. Heemsbergen, P.P. van der Toorn, Ruud C. Wortel and Peter-Paul van der Toorn and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and The Journal of Urology.

In The Last Decade

Erik C. Schimmel

16 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial

2016 329 citations Luca Incrocci, Ruud C. Wortel et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Erik C. Schimmel Netherlands	11	759	456	235	167	163	18	1.3k
Thomas P. Shakespeare Australia	19	690 0.9×	347 0.8×	286 1.2×	291 1.7×	225 1.4×	85	1.3k
Patrizia Ciammella Italy	18	770 1.0×	546 1.2×	157 0.7×	426 2.6×	225 1.4×	84	1.3k
G. Kantor France	16	584 0.8×	112 0.2×	192 0.8×	155 0.9×	307 1.9×	87	1.1k
Wendy Hara United States	25	837 1.1×	367 0.8×	673 2.9×	485 2.9×	493 3.0×	61	1.8k
B. Chauvet France	24	1.1k 1.5×	652 1.4×	602 2.6×	307 1.8×	356 2.2×	97	1.9k
Gustavo Nader Marta Brazil	20	441 0.6×	296 0.6×	354 1.5×	329 2.0×	363 2.2×	149	1.5k
Israel Deutsch United States	25	354 0.5×	151 0.3×	366 1.6×	92 0.6×	249 1.5×	44	1.6k
Ida Ackerman Canada	23	275 0.4×	437 1.0×	493 2.1×	436 2.6×	452 2.8×	39	2.0k
D. Cowen France	28	916 1.2×	331 0.7×	759 3.2×	332 2.0×	503 3.1×	75	2.3k
Matthew S. Ning United States	19	608 0.8×	171 0.4×	211 0.9×	215 1.3×	544 3.3×	89	1.4k

Countries citing papers authored by Erik C. Schimmel

Since Specialization

Citations

This map shows the geographic impact of Erik C. Schimmel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Erik C. Schimmel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Erik C. Schimmel more than expected).

Fields of papers citing papers by Erik C. Schimmel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Erik C. Schimmel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Erik C. Schimmel. The network helps show where Erik C. Schimmel may publish in the future.

Co-authorship network of co-authors of Erik C. Schimmel

This figure shows the co-authorship network connecting the top 25 collaborators of Erik C. Schimmel. A scholar is included among the top collaborators of Erik C. Schimmel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Erik C. Schimmel. Erik C. Schimmel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

So‐Osman, Cynthia, Joost S.P. Vermaat, Dick Johan van Spronsen, et al.. (2021). Treatment-specific risk of second malignancies in five-year survivors of diffuse large B-cell lymphoma.. Journal of Clinical Oncology. 39(15_suppl). 12072–12072.

Schimmel, Erik C., et al.. (2019). Projected return on investment of a corporate global health programme. BMC Public Health. 19(1). 1476–1476. 2 indexed citations

Incrocci, Luca, Ruud C. Wortel, Wendimagegn Alemayehu, et al.. (2016). Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial. The Lancet Oncology. 17(8). 1061–1069. 329 indexed citations breakdown →

Wortel, Ruud C., Luca Incrocci, Erik C. Schimmel, et al.. (2016). MP14-01 HYPOFRACTIONATED VERSUS CONVENTIONALLY FRACTIONATED RADIOTHERAPY FOR PROSTATE CANCER: 5-YEAR ONCOLOGIC OUTCOMES OF THE DUTCH RANDOMIZED PHASE 3 HYPRO TRIAL. The Journal of Urology. 195(4S). 2 indexed citations

Aluwini, Shafak, Floris J. Pos, Erik C. Schimmel, et al.. (2016). Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial. The Lancet Oncology. 17(4). 464–474. 217 indexed citations

Aluwini, Shafak, Floris J. Pos, Erik C. Schimmel, et al.. (2015). Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial. The Lancet Oncology. 16(3). 274–283. 122 indexed citations

Incrocci, Luca, Ruud C. Wortel, Shafak Aluwini, et al.. (2015). Hypofractionated Versus Conventionally Fractionated Radiation Therapy for Prostate Cancer: Five-Year Oncologic Outcomes of the Dutch Randomized Phase 3 HYPRO Trial. International Journal of Radiation Oncology*Biology*Physics. 94(1). 1–2. 6 indexed citations

Pos, Floris J., et al.. (2013). OC-0052: Late toxicity in the randomized phase III Dutch Hypofractionation Trial for prostate cancer patients (HYPRO). Radiotherapy and Oncology. 106. S19–S20. 1 indexed citations

Pos, Floris J., et al.. (2012). OC-0218 ACUTE TOXICITY OF THE RANDOMIZED PHASE III DUTCH HYPOFRACTIONATION TRIAL (HYPRO) FOR PROSTATE CANCER. Radiotherapy and Oncology. 103. S84–S85. 6 indexed citations

10.

Tol‐Geerdink, Julia J. van, J.W.H. Leer, Emile N.J.T. van Lin, Erik C. Schimmel, & Peep F. M. Stalmeier. (2011). Depression related to (neo)adjuvant hormonal therapy for prostate cancer. Radiotherapy and Oncology. 98(2). 203–206. 16 indexed citations

11.

Stalmeier, Peep F. M., Julia J. van Tol‐Geerdink, Emile N.J.T. van Lin, et al.. (2009). [The patient chooses for feasibility and effectiveness].. PubMed. 153(13). 600–6. 4 indexed citations

12.

Neelis, Karen J., Erik C. Schimmel, Maarten H. Vermeer, et al.. (2008). Low-Dose Palliative Radiotherapy for Cutaneous B- and T-Cell Lymphomas. International Journal of Radiation Oncology*Biology*Physics. 74(1). 154–158. 109 indexed citations

13.

Tol‐Geerdink, Julia J. van, J.W.H. Leer, Emile N.J.T. van Lin, et al.. (2007). Offering a Treatment Choice in the Irradiation of Prostate Cancer Leads to Better Informed and More Active Patients, Without Harm to Well-Being. International Journal of Radiation Oncology*Biology*Physics. 70(2). 442–448. 37 indexed citations

14.

Stalmeier, Peep F. M., Julia J. van Tol‐Geerdink, Emile N.J.T. van Lin, et al.. (2007). Doctors’ and Patients’ Preferences for Participation and Treatment in Curative Prostate Cancer Radiotherapy. Journal of Clinical Oncology. 25(21). 3096–3100. 69 indexed citations

15.

Tol‐Geerdink, Julia J. van, Peep F. M. Stalmeier, Emile N.J.T. van Lin, et al.. (2006). Do prostate cancer patients want to choose their own radiation treatment?. International Journal of Radiation Oncology*Biology*Physics. 66(4). 1105–1111. 41 indexed citations

16.

Belt‐Dusebout, Alexandra W. van den, Janine Nuver, Ronald de Wit, et al.. (2006). Long-Term Risk of Cardiovascular Disease in 5-Year Survivors of Testicular Cancer. Journal of Clinical Oncology. 24(3). 467–475. 246 indexed citations

17.

Tol‐Geerdink, Julia J. van, Peep F. M. Stalmeier, P.C.M. Pasker-de Jong, et al.. (2005). Systematic review of the effect of radiation dose on tumor control and morbidity in the treatment of prostate cancer by 3D-CRT. International Journal of Radiation Oncology*Biology*Physics. 64(2). 534–543. 39 indexed citations

18.

Hulshof, Maarten C.C.M., Erik C. Schimmel, D. Andries Bosch, & Dionisio González. (2000). Hypofractionation in glioblastoma multiforme. Radiotherapy and Oncology. 54(2). 143–148. 59 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact